Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.39 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | TSPO | P30536 | 1/20 | 0.39 |
| ▸ | GPR183 | P32249 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10176301 | 0.86 | CA2 (0.44) | ALDH1A1LMNACA2RXFP1ESPL1 | |
| SCHEMBL10179646 | 0.82 | HDAC4 (0.51) | ALDH1A1LMNACA2RXFP1ESPL1 | |
| SCHEMBL25643650 | 0.80 | SMN1; SMN2 (0.42) | ALDH1A1LMNACA2RXFP1ESPL1 | |
| SCHEMBL3465330 | 0.79 | ALDH1A1 (0.45) | ALDH1A1CA2 | |
| SCHEMBL8249478 | 0.79 | CA2 (0.59) | CA2 | |
| SCHEMBL30358121 | 0.79 | ALDH1A1 (0.45) | ALDH1A1CA2 | |
| SCHEMBL4631093 | 0.79 | CA2 (0.59) | CA2 | |
| SCHEMBL17061124 | 0.79 | ALDH1A1 (0.45) | ALDH1A1CA2 | |
| SCHEMBL30117178 | 0.79 | ALDH1A1 (0.45) | ALDH1A1CA2 | |
| SCHEMBL26101860 | 0.79 | ALDH1A1 (0.45) | ALDH1A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176223-B1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI SA (FR) | 2013-01-23 | — | — | EP | disclosed |
| EP-2176223-B1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI SA (FR) | 2013-01-23 | — | — | EP | disclosed |
| US-8143242-B2 | Malonamide derivatives with antithrombotic activity | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| US-8143242-B2 | Malonamide derivatives with antithrombotic activity | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| EP-2176223-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | Sanofi-Aventis (FR) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009007015-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007015-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | F7, F9, TFPI | ALDH1A1 293/4885LMNA 546/4885CA2 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.